Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 studyÉric Pujade-Lauraine, Bradley J. Monk, Keiichi Fujiwara et al.|The Lancet Oncology|2021Cited by 401
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based studyKuniko Sunami, Takashi Kohno, Eisaku Furukawa et al.|Cancer Science|2019Cited by 375
First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid TumorsToshio Shimizu, Noboru Yamamoto, Yutaka Fujiwara et al.|Clinical Cancer Research|2021Cited by 97
Trop-2 expression and the tumor immune microenvironment in cervical cancerYohei Chiba, Kan Yonemori|Gynecologic Oncology|2024Cited by 16
Changes in HER3 expression profiles between primary and recurrent gynecological cancersYuki Kojima, Kan Yonemori|Cancer Cell International|2023Cited by 12